Approval · Notice of Compliance 28260 · 2022
OXPAM: Notice of Compliance 28260
Issued May 25, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28260
- Date
- May 25, 2022
- Company
- Biomed PharmaMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph (PM) as per advisement letter and to convert the PM to the new 2020 Product Monograph Master Template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OXPAM | Not yet assigned | — |